Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study uses MRI to track fatty liver in diabetic patients

NCT ID NCT03864510

Knowledge-focused Sponsor: Linkoeping University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how common and severe fatty liver disease is in people with type 2 diabetes. Researchers used advanced MRI scans to measure liver fat, inflammation, and scarring. 317 patients were checked twice, three years apart, to see how the disease changes over time. The goal was to better understand who gets worse and why.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

317 people

The number who actually took part.

Started

Apr 2019

Finished

Dec 2023

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutively enrolled patients with diabetes type 2 in primary care.

Ages

35 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diabetes type 2 * Age 35-75 year Exclusion Criteria: * Contraindication to MR * Alcohol dependance * Previously diagnosed liver cirrhosis * Previously known liver disease (other than fatty liver)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD

Contacts and locations

Locations

  • Ekholmen primary health care centre

    Linköping, Swedish, 58185, Sweden

  • Åby primary health care centre

    Norrköping, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.